Home>Topics>Stocks>NuVasive

NuVasive NUVA

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Medtech Shifts From High Gear Into Overdrive: Canaccord's William Plovanic

      Headlines

      Wed, 20 Aug 2014

      By Life Sciences Report : Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report ,

    2. New finance chief at Cytori

      Headlines

      Mon, 18 Aug 2014

      Cytori Therapeutics ( CYTX -1.2% ) appoints Tiago Girao as VP of Finance and CFO effective September 2, 2014. He joins the firm from NuVasive where he was International Controller. Post your comment!

    3. Update: Judge Cancels NuVasive's Trademark On The NeuroVision Name

      Headlines

      Tue, 12 Aug 2014

      By Andy Batts : NuVasive 's (NASDAQ: NUVA ) bid to escape a $30 ..... negative catalyst for NuVasive 's stock, but I feel ..... it, especially after NUVA posted excellent second ..... 2010, it was found that NuVasive infringed the NeuroVision

    4. Bernanke’s Santa Claus Cheer

      Headlines

      Fri, 27 Dec 2013

      NuVasive 's fortunes are bound to spinal fusion.

    5. NuVasive ( NUVA ): Q1 EPS of $0.26 beats by $0.04. Revenue of $159.5M (+5.2% Y/Y) beats by $2.06M. (PR)

      Headlines

      Tue, 30 Apr 2013

      NuVasive ( NUVA ): Q1 EPS of $0.26 beats by $0.04 . Revenue of $159.5M (+5.2% Y/Y) beats by $2.06M . ( PR ) Post your comment!

    6. Closing the DOJ Investigation of INFUSE Comes as Good News to Medtronic

      Commentary

      Wed, 16 May 2012

      treatment. Additionally, smaller competitors such as NuVasive NUVA have introduced new biologic products that compete with ..... be bundled with its hardware and instrument systems, NuVasive has been able to attract more spinal surgeons to embrace

    7. Dropping Coverage of NuVasive

      Commentary

      Fri, 19 Aug 2011

      We are no longer providing equity research on NuVasive NUVA . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    8. NuVasive to Refinance 2013 Convertibles with New Issue

      Commentary

      Wed, 22 Jun 2011

      NuVasive NUVA announced its intentions to issue $325 ..... issue. In terms of valuation, we think NuVasive shares are about fairly valued, so we ..... a potential credit-sensitive play at NuVasive . We've seen 10-year issues of BBB

    9. In-line Fourth Quarter for NuVasive , but Uncertainty Remains in Spine Market

      Commentary

      Fri, 25 Feb 2011

      NuVasive NUVA reported fourth-quarter earnings that ..... commercial insurers still provide coverage for NuVasive 's lateral procedure though, after deeming ..... and long-term assumptions. We think NuVasive will have to largely generate growth in

    10. NuVasive Under Review

      Commentary

      Tue, 7 Dec 2010

      We are placing NuVasive NUVA under review as we update our valuation. As we noted previously, we will moderately cut our fair value estimate due to a decrease

    « Prev123Next »
    Content Partners